Swiss Longitudinal Cohort

February 14, 2020 updated by: Hypertension Excellence Centre Lucerne

The planned research project is a prospective population-based cohort study, similar to the well-known Framingham study in the United States. So far, there is no similar research project in Switzerland.

It is planned to examine of three Swiss municipalities. Recruitment in a first Swiss municipality (Lostallo/Cama GR) started 2014 and ended in 2019. Overall, 496 participants were recruited in this municipality. The five-year follow-up in this municipality started in 2019. It is planned to start recruitment in a second Swiss municipality (Uznach SG) in 2020.

The examinations embrace a broad spectrum of measurements (for details the investigators refer to the published study protocol).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Switzerland
    • Graubünden
      • Cama, Graubünden, Switzerland, CH-6557
      • Lostallo, Graubünden, Switzerland, CH-6558
    • Saint Gallen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Population of four Swiss municipalities

Description

Inclusion Criteria:

  • Resident of Cama GR, Lostallo GR, or Uznach SG
  • Age ≥6 years (no upper age limit), for voluntary blood sample ≥18 years
  • Willing to participate in long-term study
  • Written informed consent (in participants ≥6 years and <18 years signed by parents)

Exclusion Criteria:

  • No exclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Mortality
Time Frame: 10 years
10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiovascular events
Time Frame: 10 years
Cardiovascular events (i.e. stroke, myocardial infarction) will be assessed using questionnaires and case records.
10 years
Heart function
Time Frame: 10 years
Heart function will be assessed using questionnaires for symptoms, clinical examination and measurement of electromechanical activation time.
10 years
Cognitive function
Time Frame: 10 years
Cognitive function will be assessed using validated instruments.
10 years
Kidney function
Time Frame: 10 years
Kidney function will be assessed using laboratory measurements.
10 years
Autonomy
Time Frame: 10 years
Autonomy wil be assessed using validated instruments.
10 years
Nursing home admission
Time Frame: 10 years
Nursing home admissions will be assessed using standardized questions.
10 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in cardiovascular risk factors
Time Frame: 10 years
Cardiovascular risk factors will be assessed using validated measurements.
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hypertension Excellence Centre Lucerne

Investigators

  • Study Chair: Paul Erne, MD, Hypertension Excellence Centre Lucerne
  • Principal Investigator: Andreas W Schoenenberger, MD, University Department of Geriatrics, University of Bern
  • Principal Investigator: Paolo Suter, MD, University of Zurich
  • Principal Investigator: Franco Muggli, MD, Swiss Society of Hypertension
  • Principal Investigator: Renate Schoenenberger, MD, Hypertension Excellence Centre Lucerne
  • Principal Investigator: Pierre-Alexandre Krayenbühl, MD, Linth Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2014

Primary Completion (Anticipated)

September 1, 2024

Study Completion (Anticipated)

September 1, 2034

Study Registration Dates

First Submitted

October 29, 2014

First Submitted That Met QC Criteria

October 31, 2014

First Posted (Estimate)

November 4, 2014

Study Record Updates

Last Update Posted (Actual)

February 18, 2020

Last Update Submitted That Met QC Criteria

February 14, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • SNCTP 000000612

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Risk Factors

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe